Intellia Therapeutics, Inc.

NASDAQ:NTLA

Biotechnology

Healthcare
$9.77 +0.14%

+$0.02 today

Market cap
$1.37B
Beta
1.81
P/E (TTM)
-4.6
EPS (TTM)
-$3.33
52W Low $7.95High $28.25

Volume 7.23M

Average 6.11M

NTLA Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Intellia Therapeutics, Inc.NASDAQ: NTLA

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 118.49M shares rose 14.5% year over year, ahead of the +9.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 9.3% from the prior quarter. Over 3 fiscal years it compounded at +12.1% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +14.5% holds above the trailing-twelve-month pace of +9.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
118.49M+9.3% QoQ
Last fiscal yearDec 2025
108.38M+9.6% YoY
LTMMar 2026
110.2M+9.3% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.5%——
1 year+9.6%——
3-year CAGR+12.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
108.38M USD
Year-over-year change
+9.6%
4-year CAGR
+11.2%

Weighted Avg Shares (Diluted) vs competitors

How NTLA compares with its peers on the latest reported figures

  • NTLA's LTM Mar 2026 weighted avg shares (diluted) of 110.2M shares is the 4th highest of the 10 companies compared; the peer median is 94.81M shares.
  • Its year-over-year change of +9.3% is the 6th highest of 10, against a peer median of +12.7%.
  • Over three fiscal years its annual growth of +12.1% compares with a peer median of +12.2%.
NTLA Competitors Peer median
Weighted Avg Shares (Diluted) for NTLA and competitors
Company Period LTM YoY 3-year CAGR
PGENPrecigen, Inc.LTM Jun 2026334.02M +15.3%+15.0%
SANASana Biotechnology, Inc.LTM Mar 2026257.25M +9.0%+10.4%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026111.46M +12.7%+17.7%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026110.2M +9.3%+12.1%
BEAMBeam Therapeutics Inc.LTM Jun 2026103.77M +17.0%+12.2%
CRSPCRISPR Therapeutics AGLTM Sep 202694.81M +8.4%+5.0%
CRBUCaribou Biosciences, Inc.LTM Mar 202694.18M +3.6%+15.4%
EDITEditas Medicine, Inc.LTM Mar 202690.28M +9.3%+8.9%
MGTXMeiraGTx Holdings plcLTM Mar 202680.99M +13.7%+21.2%
QUREuniQure N.V.LTM Mar 202658.39M +17.2%+7.2%
Peer median (excluding NTLA) 94.81M+12.7%+12.2%

Competitors are the stored peer set for NTLA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue33.05M52.12M36.28M57.88M67.67M
Cost of Revenue6.89M7.57M8.98M10.29M15.92M
Gross Profit26.16M44.55M27.3M47.59M51.75M
Gross Margin79.2%85.5%75.3%82.2%76.5%
Research & Development229.81M419.98M435.07M466.31M388.86M
Selling, General & Admin71.1M90.31M116.5M125.83M119.8M
Operating Expenses294.01M502.71M542.59M581.86M492.74M
Depreciation & Amortization6.89M7.57M8.98M10.29M15.92M
EBITDA(261M)(466.61M)(472.22M)(508.74M)(396.77M)
EBITDA Margin-789.6%-895.3%-1301.8%-879.0%-586.3%
Operating Income(267.85M)(458.16M)(515.29M)(534.26M)(440.99M)
Operating Margin-810.4%-879.0%-1420.5%-923.1%-651.7%
Interest Income1.28M8.54M49.83M47.81M29.2M
Interest Expense00000
Other Income / Expenses(42K)(16.02M)34.1M15.24M28.3M
Income Before Tax(267.89M)(474.19M)(481.19M)(519.02M)(412.69M)
Pre-Tax Margin-810.5%-909.8%-1326.5%-896.8%-609.9%
Income Tax Expense00000
Net Income(267.89M)(474.19M)(481.19M)(519.02M)(412.69M)
Net Margin-810.5%-909.8%-1326.5%-896.8%-609.9%
EPS (Basic)(3.78)(6.16)(5.42)(5.25)(3.81)
EPS (Diluted)(3.78)(6.16)(5.42)(5.25)(3.81)
Weighted Avg Shares70.89M76.97M88.77M98.85M108.38M
Weighted Avg Shares (Diluted)70.89M76.97M88.77M98.85M108.38M

Intellia Therapeutics, Inc.

NASDAQ:NTLA

Intrinsic Alpha fair value

Locked

Current Price

$9.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.